Metastatic Disease Clinical Trial
Official title:
MAnagement of METastatic Disease In Campania (MAMETIC): Role of Radiotherapy in an Italian Region: Protocol for an Observational Multicenter Trial
The MAMETIC Trial represents the first regional epidemiological study that aims to evaluate patients living in Campania with metastatic cancer, with the intent to detect different prevalence of tumors in the metastatic phase and evaluate the local response to the patient's request for assistance. Condition or disease: Metastatic disease Intervention/treatment: Radiation Treatment
The MAMETIC Trial is a multicenter, retrospective and prospective observational study and 17 of 20 RT Centers in Campania joined it. 1. The retrospective part of the study concerns all patients enrolled with a diagnosis of metastatic disease and treated in RT centers of the Campania Region with 3DCRT, IMRT, VMAT, SBRT techniques from January 2019 to August 2020. In 2019, it has been enrolled 12.500 patients in the 17 RT Centers and it is estimated that 20-30% of the above mentioned patients had metastasis. Thus, approximately 2.560 patients are expected to be enrolled. 2. The prospective part of the study is going to enroll all metastatic patients eligible for palliative RT, treated in RT Centers of the Campania region with 3DCRT, IMRT, VMAT, SBRT techniques from September 2020 to September 2025. Considering the RT Centers that joined the trial, it is expected to enroll approximately 2.500-4.200 patients per year and a total of 12.500-21.000 patients in 5 years. The study will last 61 months, divided as follow: 60 months of enrollment phase and up to 1 month of follow-up for pain and bone metastasis patients. Follow-up will be performed on the 15th and 30th day after the end of radiation treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01450683 -
Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy
|
Phase 2 | |
| Terminated |
NCT04116164 -
Safety and Targeting of Anti-hk2 Antibody in mCRPC
|
Early Phase 1 | |
| Terminated |
NCT01020305 -
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02496832 -
A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo
|
N/A | |
| Completed |
NCT01763970 -
Stereotactic Radiation Therapy for Pediatric Sarcomas
|
N/A | |
| Completed |
NCT01703910 -
Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic
|
Phase 2 | |
| Completed |
NCT00609401 -
Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)
|
Phase 2 | |
| Completed |
NCT02628379 -
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
|
||
| Completed |
NCT00480389 -
Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal
|
Phase 2 | |
| Recruiting |
NCT03632005 -
Negative Pressure Wound Therapy vs. Sterile Dressing for Patients Undergoing Thoracolumbar Spine Surgery
|
N/A | |
| Recruiting |
NCT04492735 -
The Use of Indocyanine Green as a Diagnostic Adjunct for Pediatric Solid Malignancies
|
||
| Terminated |
NCT02175654 -
Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
|
Phase 2 | |
| Not yet recruiting |
NCT01861938 -
Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT01875380 -
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
| Terminated |
NCT00532454 -
Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen
|
Phase 2 | |
| Terminated |
NCT02795819 -
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
|
Phase 1 | |
| Recruiting |
NCT05188911 -
Analysis of Next Generation PET and Liquid Biopsy to Monitor mCRPC Treated With Abiraterone: ANGELA Trial
|
||
| Completed |
NCT03823989 -
Intravenously Administered Liposomal PROMITIL in Combination With External Beam Radiotherapy in Cancer Patients
|
Phase 1 | |
| Terminated |
NCT01904916 -
CPCT-05 Biopsy Protocol Patient Selection
|
N/A | |
| Terminated |
NCT01484860 -
Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy
|
Phase 2 |